1-5 of 5
Scott Antonia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma

Ciara L. Freeman, Reginald Atkins, Indumathy Varadarajan, Meghan Menges, Jeffrey Edelman, Rachid Baz, Jason Brayer, Omar Castaneda Puglianini, Jose Leonel Ochoa-Bayona, Taiga Nishihori, Kenneth H. Shain, Bijal Shah, Dung Tsa Chen, Linda Kelley, Domenico Coppola, Melissa Alsina, Scott Antonia, Claudio Anasetti, Frederick L. Locke
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4575–4585.
https://doi.org/10.1158/1078-0432.CCR-22-3987
Published: 14 November 2023
View article titled, Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Open the PDF for Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2313–2320.
https://doi.org/10.1158/1078-0432.CCR-21-2742
Published: 01 June 2022
View article titled, Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

Raffit Hassan, Evan Alley, Hedy Kindler, Scott Antonia, Thierry Jahan, Somayeh Honarmand, Nitya Nair, Chan C. Whiting, Amanda Enstrom, Ed Lemmens, Takahiro Tsujikawa, Sushil Kumar, Gina Choe, Anish Thomas, Katherine McDougall, Aimee L. Murphy, Elizabeth Jaffee, Lisa M. Coussens, Dirk G. Brockstedt
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5787–5798.
https://doi.org/10.1158/1078-0432.CCR-19-0070
Published: 01 October 2019
View article titled, Clinical Response of Live-Attenuated, <em>Listeria monocytogenes</em> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Open the PDF for Clinical Response of Live-Attenuated, <em>Listeria monocytogenes</em> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

Srinivas Nagaraj, Je-In Youn, Hannah Weber, Cristina Iclozan, Lily Lu, Matthew J. Cotter, Colin Meyer, Carlos R. Becerra, Mayer Fishman, Scott Antonia, Michael B. Sporn, Karen T. Liby, Bhupendra Rawal, Ji-Hyun Lee, Dmitry I. Gabrilovich
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1812–1823.
https://doi.org/10.1158/1078-0432.CCR-09-3272
Published: 14 March 2010
View article titled, Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
Open the PDF for Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Eric Haura, Francisco A. Rodriguez, David Boulware, Rachna Kapoor, Anthony M. Neuger, Richard Lush, Barbara Padilla, Michelle Burton, Charles Williams, George Simon, Scott Antonia, Daniel M. Sullivan, Gerold Bepler
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1464–1469.
https://doi.org/10.1158/1078-0432.CCR-07-1508
Published: 03 March 2008
View article titled, Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer in another window